Furthermore, interesting preliminary clinical data were obtained in a phase 1b study in which 12 patients with relapsed/refractory PTCL and CTCL received pembrolizumab in combination with pralatrexate, a dihydrofolate reductase inhibitor, or decitabine, a cytidine analog, or both pralatrexate and decitabine (98). This evidence concerns the gene DHFR and mature T-cell and NK-cell non-Hodgkin lymphoma.